Work

First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF -mutated differentiated thyroid cancer (DTC): Insights from real-world data.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.6052

Authors: Wilson Ngai, Shuyu D. Li, Shelley MacNeil, Min Ren, Shuangxi Ji, Julia Koloskova

Institutions: Eisai (United States), Tempus Labs (United States)

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162561098

Cites:

Cited by:

Related to: